Analysis Tools
immune system
| N |
• mice co-housed with wild-type mice do not affect the susceptibility to induced colitis of wild-type mice
|
|
Allele Symbol Allele Name Allele ID |
Il1btm1Lvp targeted mutation 1, Lex H T Van der Ploeg MGI:2157795 |
||||||||||||||||||||
| Summary |
4 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice co-housed with wild-type mice do not affect the susceptibility to induced colitis of wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• following infection with Sterne 34F2 strain of Bacillus anthracis
|
|
• following Sindbis virus infection, 4% of mice die compared with 88% of similarly treated wild-type mice
|
|
• only 3 of 16 mice injected with B16M cells die after 12 days compared to all similarly treated wild-type mice
(J:59893)
• following injection of B16 melanoma cells
(J:82394)
|
|
• macrophages exhibit impaired ability to kill Bacillus anthracis compared with wild-type cells
|
|
• following exposure of macrophages to LPS or Bacillus anthracis spores
|
|
• from macrophages co-cultured with B16 cells
|
|
• following infection with Sterne 34F2 strain of Bacillus anthracis
|
|
• neuroadapted Sindbis virus-infected mice exhibit attenuated hind limb paralysis and spinal cord motor neuron degeneration compared with similarly treated wild-type mice
|
|
• mice infected with Sindbis virus exhibit altered viral spread and reduced severe paralysis and death compared with similarly treated wild-type mice
• however, apoptosis and lesions in the brain following infection are the same as in wild-type mice
|
|
• following Sindbis virus infection, 4% of mice die compared with 88% of similarly treated wild-type mice
|
|
• angiogenesis in mice injected with B16 melanoma cells is nearly absent compared to in similarly treated wild-type mice
|
|
• mice injected with B16 cells exhibit reduced metastasis (by volume and density) in the liver compared with similarly treated wild-type mice
(J:59893)
• mice injected with B16 cells exhibit decreased metastasis volume, an indicator of metastatic growth, compared with similarly treated wild-type mice
(J:59893)
• following injection of B16 melanoma cells, no metastatic tumors are observed unlike in similarly treated wild-type mice
(J:82394)
• mice injected with mammary cancer tumor DA/3 exhibit slower and smaller tumor development compared with similarly treated wild-type mice
(J:82394)
|
|
• mice injected with B16 cells exhibit decreased metastasis volume, an indicator of metastatic growth, compared with similarly treated wild-type mice
(J:59893)
• mice injected with mammary cancer tumor DA/3 exhibit slower and smaller tumor development compared with similarly treated wild-type mice
(J:82394)
|
|
• angiogenesis in mice injected with B16 melanoma cells is nearly absent compared to in similarly treated wild-type mice
|
|
• following arterial ligation, mice exhibit reduced and smaller cerebral aneurysm with reduced ssDNA and TUNEL+ cells in the vascular walls compared with similarly treated wild-type mice
|
|
• macrophages exhibit impaired ability to kill Bacillus anthracis compared with wild-type cells
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• following acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis
|
|
• following acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis, popliteal and inguinal lymph node mononuclear cell proliferation is reduced compared to in similarly treated wild-type mice
• however, anti-CD3-induced T cell proliferation is normal
|
|
• mice fail to produce IL-1 beta at a basal level or in response to LPS administration
|
|
• following acetylcholine receptor-stimulation of popliteal and inguinal lymph node mononuclear cells
|
|
• following acetylcholine receptor-stimulation of popliteal and inguinal lymph node mononuclear cells
|
|
• following acetylcholine receptor-stimulation of popliteal and inguinal lymph node mononuclear cells
|
|
• mice fail to increase plasma levels of IL-6 in response to the turpentine injection
• in contrast, control mice have a peak of plasma IL-6 levels about 10-fold above basal 8 hours after injection with levels remaining above basal for at least 96 hours post-injection
|
|
• mice are resistant to acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis (decreased mortality, muscle weakness, lymphocyte proliferation, Th1 and Th2 cytokine production, and serum acetylcholine receptor antibodies) compared with similarly treated wild-type mice
|
|
• some of the long-term side effects of the inflammatory response to turpentine does not occur in these mice
• these side effects include loss of weight, decrease food and water intake
• influx of white blood cells to the injection site occurs in a manner similar to wild-type mice
|
|
• mice fail to develop a fever in response to the inflammatory agent turpentine
• mice also fail to increase plasma levels of IL-6 in response to the turpentine injection
• there is a 2- to 5- fold reduction in mRNA transcripts for acute-phase proteins after 8- to 72 hours after turpentine injection
|
|
• mice fail to produce IL-1 beta at a basal level or in response to LPS administration
|
|
• mice fail to develop a fever in response to the inflammatory agent turpentine
• in contrast, mice develop a fever starting 5 hours after administration that lasts for 24 hours
• control mice also have a decrease in locomotor activity the night after injection while mutant mice have normal activity
|
|
• following acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis, popliteal and inguinal lymph node mononuclear cell proliferation is reduced compared to in similarly treated wild-type mice
• however, anti-CD3-induced T cell proliferation is normal
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• following corticectomy injury, mice exhibit delayed re-establishment of the blood-brain barrier compared with similarly treated wild-type mice
|
|
• following corticectomy injury, mice exhibit reduced GFAP immunoreactivity and delayed re-establishment of the blood-brain barrier compared with similarly treated wild-type mice until day 5
|
|
• following corticectomy injury, mice exhibit delayed re-establishment of the blood-brain barrier compared with similarly treated wild-type mice
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/23/2024 MGI 6.23 |
|
|
|
||